COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,846 Articles (22,553 medRxiv, 8,293 bioRxiv)

Most recent first Previous |  Page 1182: Articles 11811-11820  | Next

Cohort Study: The Accuracy of Screening Methods of COVID-19 in Pregnancy: Practical Approach in Low Resources Health Services
Aldika Akbar, M. I., Gumilar, K. E., Rahestyningtyas, E., Wardhana, M. P., Mulawardhana, P., Anas, J. Y., Ernawati, E., Cahya Laksana, M. A., Joewono, H. T.
10.1101/2021.09.20.21263866 — Posted: 2021-09-26
Unrecognized introductions of SARS-CoV-2 into the state of Georgia shaped the early epidemic
Babiker, A., Martin, M. A., Marvil, C., Bellman, S., Petit, R. A., Bradley, H. L., Stittleburg, V. D., Ingersoll, J. M., Kraft, C. S., Read, T. D., Waggoner, J. J., Koelle, K., Piantadosi, A.
10.1101/2021.09.19.21262615 — Posted: 2021-09-25 Discussion: Onsite
Protein Vaccine Induces a Durable, More Broadly Neutralizing Antibody Response in Macaques than Natural Infection with SARS-CoV-2 P.1
To, A., Wong, T. A. S., Lieberman, M. M., Thompson, K. S., Pessaint, L., Greenhouse, J., Daham, N., Cook, A., Narvaez, B., Flinchbaugh, Z., Van Ry, A., Yalley-Ogunro, J., Andersen, H., Lai, C.-Y., Donini, O., Lehrer, A. T.
10.1101/2021.09.24.461759 — Posted: 2021-09-25
COVID-19 mortality risk correlates inversely with vitamin D3 status, and a mortality rate close to zero could theoretically be achieved at 50 ng/ml 25(OH)D3: Results of a systematic review and meta-analysis
Borsche, L., Glauner, B., von Mendel, J.
10.1101/2021.09.22.21263977 — Posted: 2021-09-25 Discussion: Onsite | Offsite
A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and disease
Higdon, M. M., Wahl, B., Jones, C. B., Rosen, J. G., Truelove, S. A., Baidya, A., Nande, A. A., ShamaeiZadeh, P. A., Walter, K. K., Feikin, D. R., Patel, M. K., Deloria Knoll, M., Hill, A. L.
10.1101/2021.09.17.21263549 — Posted: 2021-09-25
LRRC15 mediates an accessory interaction with the SARS-CoV-2 spike protein
Shilts, J., Crozier, T. M., Teixeira-Silva, A., Gabaev, I., Greenwood, E. J. D., Watson, S. J., Ortmann, B. M., Gawden-Bone, C. M., Pauzaite, T., Hoffmann, M., Nathan, J. A., Pöhlmann, S., Lehner, P. J., Wright, G. J.
10.1101/2021.09.25.461776 — Posted: 2021-09-25
Caspase-4/11 exacerbates disease severity in SARS-CoV-2 infection by promoting inflammation and thrombosis
Eltobgy, M., Zani, A., Kenney, A., Estfanous, S., Kim, E., Badr, A., Carafice, C., Daily, K., Whitham, O., Pietrzak, M., Webb, A., Kawahara, J., Eddy, A., Denz, P., Lu, M., KC, M., Peeples, M., Li, J., Zhu, J., Que, J., Robinson, R., Rosas Mejia, O., Rayner, R., Hall-Stoodley, L., Seveau, S., Gavrilin, M. A., Tedeschi, A., Partida-Sanchez, S., Roberto, F., Hemann, E., Abdelrazik, E., Forero, A., Nimjee, S., Boyaka, P., Cormet-Boyaka, E., Yount, J., Amer, A.
10.1101/2021.09.24.461743 — Posted: 2021-09-25
LIGHTHOUSE illuminates therapeutics for a variety of diseases including COVID-19
Shimizu, H., Kodama, M., Matsumoto, M., Orba, Y., Sasaki, M., Sato, A., Sawa, H., Nakayama, K. I.
10.1101/2021.09.25.461785 — Posted: 2021-09-25
Screening key genes and signaling pathways in COVID-19 infection and its associated complications by integrated bioinformatics analysis
Vastrad, B. M., Vastrad, C. M.
10.1101/2021.09.24.461631 — Posted: 2021-09-25
Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD
Ma, H., Guo, Y., Tang, H., Tseng, C.-T., Wang, L., Zong, H., Wang, Z., He, Y., Chang, Y., Wang, S., Huang, H., Ke, Y., Yuan, Y., Wu, M., Zhang, Y., Drelich, A., Kempaiah, K., Peng, B.-H., Wang, A., Yang, K., Yin, H., Liu, J., Yue, Y., Xu, W., Zhu, S., Ji, T., Zhang, X., Wang, Z., Li, G., Liu, G., Song, J., Mu, L., Xiang, Z., Song, Z., Chen, H., Bian, Y., Zhang, B., Chen, H., Zhang, J., Liao, Y., Zhang, L., Yang, L., Chen, Y., Gilly, J., Xiao, X., Han, L., Jiang, H., Xie, Y., Zhou, Q., Zhu, J.
10.1101/2021.09.24.461616 — Posted: 2021-09-25

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).